cefixime has been researched along with Gonorrhea in 159 studies
Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.
Gonorrhea: Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To treat Neisseria gonorrhoeae infection, the Centers for Disease Control and Prevention recommends a single oral dose of cefixime as an alternative to injectable ceftriaxone." | 9.41 | Effectiveness of Cefixime for the Treatment of Neisseria gonorrhoeae Infection at 3 Anatomic Sites: A Systematic Review and Meta-Analysis. ( Bristow, CC; Klausner, JD; Kojima, N; Yang, KJ, 2023) |
| "Comparator studies reporting adverse effect outcomes of treatment with cefixime, ceftriaxone, or gentamicin for gonorrhea in humans were included." | 9.12 | Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis. ( Dresser, J; Wilby, KJ, 2021) |
| "Both intramuscular ceftriaxone 125 mg and oral cefixime 400 mg appear to be effective for the treatment of gonococcal infection in pregnancy." | 9.09 | A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. ( Mayfield, JA; Ramus, RM; Sheffield, JS; Wendel, GD, 2001) |
| " During 1996-1997, 105 female sex workers with gonorrhea were prospectively randomized to receive treatment with oral ciprofloxacin, 500 mg, or cefixime, 400 mg, and followed for test of cure." | 9.09 | A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines. ( Aplasca De Los Reyes, MR; Dallabetta, G; Holmes, KK; Klausner, JD; Manalastas, R; Pato-Mesola, V; Tuazon, CU; Whittington, WL; Wi, T, 2001) |
| "In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg)." | 9.08 | Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group. ( Bean, K; Hook, EW; Jones, RB; Maroli, AN; Martin, D; McCormack, WM, 1997) |
| "In a randomized, unblinded multicenter study of 209 men and 124 women with uncomplicated gonorrhea, we compared three single-dose treatment regimens: 400 mg or 800 mg of cefixime, administered orally, and 250 mg of ceftriaxone administered intramuscularly." | 9.07 | A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. ( Covino, JM; Douglas, JM; Ehret, JM; Handsfield, HH; Hook, EW; McCormack, WM; Reichart, CA; Verdon, MS, 1991) |
| "In this randomized study, a single 800-mg oral dose of cefixime cured 96 of 97 men with uncomplicated gonococcal urethritis, compared with 44 cures of 46 men who received standard therapy with amoxicillin (3 g) plus probenecid (1 g)." | 9.06 | Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men. ( Bowie, WR; Lefebvre, K; Megran, DW; Willetts, V, 1990) |
| "Gentamicin has been used for the treatment of gonorrhea in Malawi since 1993." | 8.12 | Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi. ( Bonongwe, N; Chen, JS; Chikaonda, T; Cohen, MS; Golparian, D; Hobbs, MM; Hoffman, IF; Jere, E; Kamtambe, B; Krysiak, R; Massa, C; Mathiya, E; Matoga, M; Ndalama, B; Unemo, M, 2022) |
| "Both regimens were highly effective in treating gonorrhea with success rates of 96." | 7.11 | Randomized controlled trial of the relative efficacy of high-dose intravenous ceftriaxone and oral cefixime combined with doxycycline for the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae co-infection. ( Nguyen, HT; Nguyen, HV; Nguyen, PTT; Pham, HV; Pham, LV; Van, DH, 2022) |
| "To treat Neisseria gonorrhoeae infection, the Centers for Disease Control and Prevention recommends a single oral dose of cefixime as an alternative to injectable ceftriaxone." | 5.41 | Effectiveness of Cefixime for the Treatment of Neisseria gonorrhoeae Infection at 3 Anatomic Sites: A Systematic Review and Meta-Analysis. ( Bristow, CC; Klausner, JD; Kojima, N; Yang, KJ, 2023) |
| " Subsequently, a dosing interval of 6 h was tested in 6 healthy Japanese men, and then 93 Japanese men with gonococcal urethritis were treated with a regimen of two 200-mg doses of cefixime given at a 6-h interval." | 5.32 | Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. ( Deguchi, T; Harada, Y; Ishida, K; Ishihara, S; Ito, M; Kojima, K; Maeda, S; Minamidate, K; Tamaki, M; Tei, K; Yasuda, M; Yokoi, S, 2003) |
| "Cefixime is a new third generation oral cephalosporin that exhibits excellent antibacterial activity against Neisseria gonorrhoeae, including beta-lactamase-positive strains." | 5.28 | [Cefixime therapy in patients with proven gonorrhea]. ( Backhaus, A; Tinzl, J, 1990) |
| "Comparator studies reporting adverse effect outcomes of treatment with cefixime, ceftriaxone, or gentamicin for gonorrhea in humans were included." | 5.12 | Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis. ( Dresser, J; Wilby, KJ, 2021) |
| "Both intramuscular ceftriaxone 125 mg and oral cefixime 400 mg appear to be effective for the treatment of gonococcal infection in pregnancy." | 5.09 | A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. ( Mayfield, JA; Ramus, RM; Sheffield, JS; Wendel, GD, 2001) |
| " During 1996-1997, 105 female sex workers with gonorrhea were prospectively randomized to receive treatment with oral ciprofloxacin, 500 mg, or cefixime, 400 mg, and followed for test of cure." | 5.09 | A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines. ( Aplasca De Los Reyes, MR; Dallabetta, G; Holmes, KK; Klausner, JD; Manalastas, R; Pato-Mesola, V; Tuazon, CU; Whittington, WL; Wi, T, 2001) |
| "In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg)." | 5.08 | Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group. ( Bean, K; Hook, EW; Jones, RB; Maroli, AN; Martin, D; McCormack, WM, 1997) |
| "In a randomized, unblinded multicenter study of 209 men and 124 women with uncomplicated gonorrhea, we compared three single-dose treatment regimens: 400 mg or 800 mg of cefixime, administered orally, and 250 mg of ceftriaxone administered intramuscularly." | 5.07 | A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. ( Covino, JM; Douglas, JM; Ehret, JM; Handsfield, HH; Hook, EW; McCormack, WM; Reichart, CA; Verdon, MS, 1991) |
| "In this randomized study, a single 800-mg oral dose of cefixime cured 96 of 97 men with uncomplicated gonococcal urethritis, compared with 44 cures of 46 men who received standard therapy with amoxicillin (3 g) plus probenecid (1 g)." | 5.06 | Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men. ( Bowie, WR; Lefebvre, K; Megran, DW; Willetts, V, 1990) |
| "Gentamicin has been used for the treatment of gonorrhea in Malawi since 1993." | 4.12 | Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi. ( Bonongwe, N; Chen, JS; Chikaonda, T; Cohen, MS; Golparian, D; Hobbs, MM; Hoffman, IF; Jere, E; Kamtambe, B; Krysiak, R; Massa, C; Mathiya, E; Matoga, M; Ndalama, B; Unemo, M, 2022) |
| "Oral cefixime or ceftriaxone injections were used as first-line drugs for the treatment of gonorrhea from 2006 to 2013 because gonorrhea isolates had low minimum inhibitory concentrations for these two drugs." | 3.83 | Changes in the six most common sequence types of Neisseria gonorrhoeae, including ST4378, identified by surveillance of antimicrobial resistance in northern Taiwan from 2006 to 2013. ( Cheng, CW; Li, LH; Li, SY; Su, CY; Yen, MY, 2016) |
| "Although cephalosporins are the cornerstone of treatment of Neisseria gonorrhoeae infections, cefixime is the only oral antimicrobial option." | 3.79 | Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. ( Allen, VG; Lee, C; Low, DE; Martin, IE; Melano, RG; Mitterni, L; Rebbapragada, A; Seah, C; Siebert, H; Towns, L, 2013) |
| "Recently, the first Neisseria gonorrhoeae strain (H041) highly resistant to the expanded-spectrum cephalosporins (ESCs) ceftriaxone and cefixime, which are the last remaining options for first-line gonorrhea treatment, was isolated in Japan." | 3.78 | High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. ( Gallay, A; Golparian, D; Nicholas, R; Ohnishi, M; Sednaoui, P; Unemo, M, 2012) |
| "Ciprofloxacin resistant gonorrhea (CRG) cultures rose from 1." | 3.75 | Antimicrobial resistance in gonorrhea: the influence of epidemiologic and laboratory surveillance data on treatment guidelines: Alberta, Canada 2001-2007. ( Boyington, C; Lovgren, M; Plitt, S; Read, R; Singh, AE; Sutherland, K; Tilley, P, 2009) |
| "Both regimens were highly effective in treating gonorrhea with success rates of 96." | 3.11 | Randomized controlled trial of the relative efficacy of high-dose intravenous ceftriaxone and oral cefixime combined with doxycycline for the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae co-infection. ( Nguyen, HT; Nguyen, HV; Nguyen, PTT; Pham, HV; Pham, LV; Van, DH, 2022) |
| " Drug concentrations over time will be used to develop mathematical models for optimisation of drug dosing regimens and to estimate pharmacodynamic targets of efficacy." | 3.11 | Optimisation of treatments for oral ( Chow, EPF; Fairley, CK; Hammoud, MA; Hocking, JS; Kong, FYS; Landersdorfer, CB; Latch, N; Lewis, DA; Lim, SH; Parker, SL; Roberts, JA; Unemo, M; Wallis, SC; Williamson, DA; Yap, T, 2022) |
| "We conducted an open-label, nonrandomized, phase I pharmacokinetic and safety study of cefixime in 25 healthy male and female volunteers divided into 4 dosing cohorts (cohort A, 400 mg; cohort B, 800 mg; cohort C, 1200 mg; and cohort D, 800 mg every 8 hours × 3 doses [total dose 2400 mg]) with a target serum concentration of at least 2." | 2.87 | A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx. ( Barbee, LA; Blumer, JL; Golden, MR; Gray, W; Griffiss, JM; Nayak, SU; OʼRiordan, MA; Zenilman, JM, 2018) |
| "10) or adverse effects (OR 1." | 2.48 | Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials. ( Bai, ZG; Bao, XJ; Cheng, WD; Li, YP; Yang, KH, 2012) |
| " Acquisition of plasmids from other bacteria and long-term use of a single agent has selected both single step high-level and low-level resistance due to multiple mutations." | 2.47 | Antimicrobial resistance in Neisseria gonorrhoeae in the UK: surveillance and management. ( Alexander, S; Ison, CA, 2011) |
| "Oral regimens for the treatment of gonorrhea are limited." | 2.46 | Emergence and spread of drug resistant Neisseria gonorrhoeae. ( Deguchi, T; Maeda, S; Nakane, K; Yasuda, M, 2010) |
| "We present a case of gonococcal septic arthritis of the right hip diagnosed via synovial fluid cultures." | 1.72 | Right hip gonococcal septic arthritis treatment with successful transition to oral fluoroquinolone. ( Kiamos, A; Sands, M; Torrente, N; Verdecia, J, 2022) |
| "Cefixime resistance was detected in 2." | 1.48 | Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. ( Amato-Gauci, AJ; Cole, MJ; Day, MJ; Jacobsson, S; Spiteri, G; Unemo, M; Woodford, N, 2018) |
| "Ciprofloxacin resistance was seen in < 5% of isolates prior to 2010, but in > 5% thereafter." | 1.48 | High levels of susceptibility to new and older antibiotics in Neisseria gonorrhoeae isolates from Saskatchewan (2003-15): time to consider point-of-care or molecular testing for precision treatment? ( Dillon, JR; Horsman, GB; Levett, PN; Thakur, SD, 2018) |
| "Cefixime was recommended as a single-dose treatment for gonorrhoea from 2005 to 2010, during which time resistance increased, and subsequently declined." | 1.46 | Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: A modelling study. ( Didelot, X; White, PJ; Whittles, LK, 2017) |
| "The EC 50 of the dose-response curves correlated well with Etest MIC values (Pearson's r = 0." | 1.46 | A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae. ( Althaus, CL; Desilvestro, V; Foerster, S; Hathaway, LJ; Unemo, M, 2017) |
| "Cefixime resistance was detected in 13 (61." | 1.42 | Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance. ( Cole, MJ; Grigorjev, V; Jacobsson, S; Pitt, R; Spiteri, G; Unemo, M, 2015) |
| "gonorrhea control efforts, but treatment of gonorrhea has been complicated by the ability of Neisseria gonorrhoeae to develop antimicrobial resistance." | 1.38 | Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. ( , 2012) |
| "Gonorrhea is a worldwide sexually transmitted disease (STD) caused by Neisseria gonorrhoeae." | 1.33 | Gonorrhea: update. ( Little, JW, 2006) |
| " Subsequently, a dosing interval of 6 h was tested in 6 healthy Japanese men, and then 93 Japanese men with gonococcal urethritis were treated with a regimen of two 200-mg doses of cefixime given at a 6-h interval." | 1.32 | Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. ( Deguchi, T; Harada, Y; Ishida, K; Ishihara, S; Ito, M; Kojima, K; Maeda, S; Minamidate, K; Tamaki, M; Tei, K; Yasuda, M; Yokoi, S, 2003) |
| "Cefixime was kept for patients not responding to the first GU treatment." | 1.31 | Cost-effectiveness of management strategies for acute urethritis in the developing world. ( Crabbé, F; de Clerck, M; Laga, M; Vuylsteke, B, 2000) |
| "Cefixime is a new third generation oral cephalosporin that exhibits excellent antibacterial activity against Neisseria gonorrhoeae, including beta-lactamase-positive strains." | 1.28 | [Cefixime therapy in patients with proven gonorrhea]. ( Backhaus, A; Tinzl, J, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.63) | 18.7374 |
| 1990's | 13 (8.18) | 18.2507 |
| 2000's | 21 (13.21) | 29.6817 |
| 2010's | 85 (53.46) | 24.3611 |
| 2020's | 39 (24.53) | 2.80 |
| Authors | Studies |
|---|---|
| Kueakulpattana, N | 1 |
| Wannigama, DL | 1 |
| Luk-In, S | 1 |
| Hongsing, P | 1 |
| Hurst, C | 1 |
| Badavath, VN | 1 |
| Jenjaroenpun, P | 2 |
| Wongsurawat, T | 2 |
| Teeratakulpisan, N | 1 |
| Kerr, SJ | 1 |
| Abe, S | 1 |
| Phattharapornjaroen, P | 1 |
| Shein, AMS | 1 |
| Saethang, T | 1 |
| Chantaravisoot, N | 1 |
| Amarasiri, M | 1 |
| Higgins, PG | 1 |
| Chatsuwan, T | 1 |
| Matoga, M | 1 |
| Chen, JS | 1 |
| Krysiak, R | 1 |
| Ndalama, B | 1 |
| Massa, C | 1 |
| Bonongwe, N | 1 |
| Mathiya, E | 1 |
| Kamtambe, B | 1 |
| Jere, E | 1 |
| Chikaonda, T | 1 |
| Golparian, D | 7 |
| Unemo, M | 30 |
| Cohen, MS | 1 |
| Hobbs, MM | 1 |
| Hoffman, IF | 2 |
| Allen, H | 2 |
| Merrick, R | 1 |
| Ivanov, Z | 1 |
| Pitt, R | 2 |
| Mohammed, H | 1 |
| Sinka, K | 1 |
| Hughes, G | 4 |
| Fifer, H | 1 |
| Cole, MJ | 16 |
| Lin, X | 2 |
| Qin, X | 2 |
| Wu, X | 2 |
| Liao, Y | 2 |
| Yu, Y | 1 |
| Xie, Q | 2 |
| Tang, S | 1 |
| Guo, C | 1 |
| Pei, J | 1 |
| Wu, Z | 1 |
| Cai, C | 1 |
| Wang, F | 1 |
| Wu, S | 1 |
| Chen, H | 1 |
| Liu, X | 2 |
| Li, M | 1 |
| Cao, W | 2 |
| Zheng, H | 2 |
| Lahra, MM | 2 |
| Escher, M | 1 |
| Eremin, S | 1 |
| Galarza, P | 3 |
| Ndowa, F | 2 |
| Martin, I | 5 |
| Dillon, JR | 3 |
| Galas, M | 1 |
| Ramon-Pardo, P | 1 |
| Weinstock, H | 4 |
| Wi, T | 3 |
| Sánchez-Busó, L | 1 |
| Spiteri, G | 9 |
| Day, M | 3 |
| Jacobsson, S | 8 |
| Sajedi, N | 2 |
| Yeats, CA | 1 |
| Abudahab, K | 1 |
| Underwood, A | 1 |
| Bluemel, B | 1 |
| Aanensen, DM | 1 |
| Day, MJ | 2 |
| Kulishev, C | 1 |
| Woodford, N | 4 |
| Blumel, B | 1 |
| van der Werf, MJ | 1 |
| Amato-Gauci, AJ | 5 |
| Nguyen, PTT | 1 |
| Pham, HV | 1 |
| Van, DH | 1 |
| Pham, LV | 1 |
| Nguyen, HT | 1 |
| Nguyen, HV | 1 |
| Allan-Blitz, LT | 2 |
| Adamson, PC | 1 |
| Klausner, JD | 6 |
| Jorge-Berrocal, A | 1 |
| Vargas-Herrera, N | 1 |
| Benites, C | 1 |
| Salazar-Quispe, F | 1 |
| Mayta-Barrios, M | 1 |
| Barrios-Cárdenas, YJ | 1 |
| Melano, RG | 4 |
| Yagui, M | 1 |
| Nokchan, N | 1 |
| Nitayanon, P | 1 |
| Tribuddharat, C | 1 |
| Schörner, MA | 1 |
| Mesa, D | 1 |
| Barazzetti, FH | 1 |
| Martins, JM | 1 |
| Machado, HM | 1 |
| Grisard, HBDS | 1 |
| Wachter, JK | 1 |
| Starick, MR | 1 |
| Scheffer, MC | 1 |
| Palmeiro, JK | 1 |
| Bazzo, ML | 1 |
| Shimuta, K | 4 |
| Takahashi, H | 1 |
| Akeda, Y | 1 |
| Nakayama, SI | 1 |
| Ohnishi, M | 6 |
| Kiamos, A | 1 |
| Torrente, N | 1 |
| Sands, M | 1 |
| Verdecia, J | 1 |
| Tang, EC | 1 |
| Johnson, KA | 1 |
| Alvarado, L | 1 |
| Burghardt, NO | 1 |
| Hernandez, C | 1 |
| Lopez, E | 1 |
| Jenkins-Barnes, T | 1 |
| Hughes, B | 1 |
| Salas, KL | 1 |
| Jacobson, KR | 1 |
| Kong, FYS | 1 |
| Lim, SH | 1 |
| Latch, N | 1 |
| Williamson, DA | 1 |
| Roberts, JA | 1 |
| Wallis, SC | 1 |
| Parker, SL | 1 |
| Landersdorfer, CB | 1 |
| Yap, T | 1 |
| Fairley, CK | 1 |
| Chow, EPF | 1 |
| Lewis, DA | 2 |
| Hammoud, MA | 1 |
| Hocking, JS | 1 |
| Yang, KJ | 1 |
| Kojima, N | 1 |
| Bristow, CC | 1 |
| Xiu, L | 1 |
| Wang, L | 1 |
| Li, Y | 1 |
| Hu, L | 1 |
| Huang, J | 1 |
| Yong, G | 1 |
| Wang, Y | 1 |
| Dong, Y | 1 |
| Gu, W | 1 |
| Peng, J | 1 |
| Lin, HH | 1 |
| Li, JW | 1 |
| Yang, TY | 1 |
| Lee, CY | 1 |
| Jain, SH | 1 |
| Lin, SY | 1 |
| Lu, PL | 1 |
| Riou, J | 1 |
| Althaus, CL | 3 |
| Grad, YH | 4 |
| Heijne, JCM | 1 |
| Low, N | 1 |
| Li, X | 1 |
| Yin, X | 1 |
| Liu, M | 1 |
| Pan, Y | 1 |
| Zeng, L | 1 |
| Yang, J | 1 |
| Feng, Z | 1 |
| Tang, Y | 1 |
| Chen, W | 1 |
| Luo, X | 1 |
| Zhuang, P | 1 |
| Li, R | 1 |
| Blouin, K | 1 |
| Lefebvre, B | 2 |
| Trudelle, A | 1 |
| Defay, F | 1 |
| Perrault Sullivan, G | 1 |
| Ezin Aloffan, LND | 1 |
| Labbé, AC | 1 |
| Yasuda, M | 7 |
| Takahashi, S | 2 |
| Miyazaki, J | 1 |
| Wada, K | 1 |
| Kobayashi, K | 1 |
| Matsumoto, M | 1 |
| Hayami, H | 1 |
| Yamamoto, S | 1 |
| Kiyota, H | 1 |
| Sato, J | 1 |
| Matsumoto, T | 1 |
| Yotsuyanagi, H | 1 |
| Hanaki, H | 1 |
| Masumori, N | 1 |
| Hiyama, Y | 2 |
| Nishiyama, H | 1 |
| Kimura, T | 1 |
| Yamada, H | 1 |
| Matsumoto, K | 1 |
| Ishikawa, K | 1 |
| Togo, Y | 1 |
| Tanaka, K | 1 |
| Sadahira, T | 1 |
| Inokuchi, J | 1 |
| Hamasuna, R | 1 |
| Ito, K | 1 |
| Hirayama, H | 1 |
| Hayashi, K | 1 |
| Kurimura, Y | 2 |
| Kadena, H | 1 |
| Ito, S | 5 |
| Shiono, Y | 1 |
| Maruyama, T | 1 |
| Ito, M | 3 |
| Hatano, K | 1 |
| Chokyu, H | 1 |
| Ihara, H | 1 |
| Uno, S | 1 |
| Monden, K | 1 |
| Yokoyama, T | 1 |
| Kano, M | 1 |
| Kaji, S | 1 |
| Kawahara, M | 1 |
| Sumii, T | 1 |
| Tojo, T | 1 |
| Hosobe, T | 1 |
| Naito, K | 1 |
| Kawai, S | 1 |
| Nishimura, H | 1 |
| Izumitani, M | 1 |
| Yoh, M | 1 |
| Matsumura, M | 1 |
| Fujita, R | 1 |
| Takayama, K | 1 |
| Hara, M | 1 |
| Nishi, S | 1 |
| Ma, A | 1 |
| Ferrato, C | 1 |
| Smyczek, P | 1 |
| Gratrix, J | 3 |
| Dingle, TC | 1 |
| Deng, X | 2 |
| Młynarczyk-Bonikowska, B | 1 |
| Majewska, A | 1 |
| Malejczyk, M | 1 |
| Młynarczyk, G | 1 |
| Majewski, S | 1 |
| Quinten, C | 1 |
| Indriatmi, W | 1 |
| Prayogo, RL | 1 |
| Nilasari, H | 1 |
| Suseno, LS | 1 |
| Palavecino, EL | 1 |
| Kilic, A | 1 |
| Schmerer, MW | 1 |
| Dobre-Buonya, O | 1 |
| Toler, C | 1 |
| McNeil, CJ | 1 |
| Workneh, M | 1 |
| Hamill, MM | 1 |
| Kakooza, F | 1 |
| Mande, E | 1 |
| Wagner, J | 1 |
| Mbabazi, O | 1 |
| Mugasha, R | 1 |
| Kajumbula, H | 1 |
| Walwema, R | 1 |
| Zenilman, J | 1 |
| Musinguzi, P | 1 |
| Kyambadde, P | 1 |
| Lamorde, M | 1 |
| Manabe, YC | 1 |
| Pinto, M | 1 |
| Matias, R | 1 |
| Rodrigues, JC | 1 |
| Duarte, S | 1 |
| Vieira, L | 1 |
| Gonçalves, I | 1 |
| Gonçalves, MJ | 1 |
| Ramos, MH | 1 |
| Gomes, JP | 1 |
| Borrego, MJ | 1 |
| Selb, R | 1 |
| Jansen, K | 3 |
| Eckardt, M | 1 |
| Tamminga, T | 2 |
| Dudareva, S | 3 |
| Gassowski, M | 1 |
| Graeber, I | 2 |
| Guhl, E | 3 |
| Heuer, D | 2 |
| Buder, S | 3 |
| Dresser, J | 1 |
| Wilby, KJ | 1 |
| Banhart, S | 1 |
| Calvignac-Spencer, S | 1 |
| Pilz, T | 1 |
| Martini, A | 1 |
| Nikisins, S | 2 |
| Dehmel, K | 1 |
| Zuelsdorf, G | 1 |
| Kohl, PK | 4 |
| Bremer, V | 2 |
| Miller, S | 1 |
| Degener, T | 1 |
| Patel, P | 1 |
| Picker, MA | 1 |
| Knoblock, RJ | 1 |
| Hansen, H | 1 |
| Bautista, I | 1 |
| Griego, R | 1 |
| Barber, L | 1 |
| Bendik, W | 1 |
| Lam, K | 1 |
| Adelman, E | 1 |
| Qiu-Shultz, Z | 1 |
| Raphael, BH | 1 |
| Pham, CD | 1 |
| Kersh, EN | 1 |
| St Cyr, SB | 1 |
| Oree, G | 1 |
| Naicker, M | 1 |
| Maise, HC | 1 |
| Tinarwo, P | 1 |
| Ramsuran, V | 1 |
| Abbai, NS | 1 |
| Eyre, DW | 2 |
| De Silva, D | 2 |
| Cole, K | 2 |
| Peters, J | 2 |
| Demczuk, W | 1 |
| Mulvey, MR | 1 |
| Crook, DW | 2 |
| Walker, AS | 2 |
| Peto, TEA | 1 |
| Paul, J | 2 |
| Foerster, S | 1 |
| Desilvestro, V | 1 |
| Hathaway, LJ | 1 |
| Latif, AS | 1 |
| Gwanzura, L | 1 |
| Machiha, A | 1 |
| Tarupiwa, A | 1 |
| Gudza-Mugabe, M | 1 |
| Shukusho, FD | 1 |
| Chakanyuka Musanhu, C | 1 |
| Gianecini, R | 2 |
| Romero, MLM | 1 |
| Oviedo, C | 2 |
| Vacchino, M | 1 |
| Tripodo, F | 1 |
| Thakur, SD | 3 |
| Levett, PN | 3 |
| Horsman, GB | 3 |
| Whittles, LK | 1 |
| White, PJ | 1 |
| Didelot, X | 2 |
| Papp, JR | 1 |
| Rowlinson, MC | 1 |
| O'Connor, NP | 1 |
| Wholehan, J | 1 |
| Razeq, JH | 1 |
| Glennen, A | 1 |
| Ware, D | 1 |
| Iwen, PC | 1 |
| Lee, LV | 1 |
| Hagan, C | 1 |
| Loenenbach, A | 1 |
| Sailer, A | 1 |
| Comunián-Carrasco, G | 1 |
| Peña-Martí, GE | 1 |
| Martí-Carvajal, AJ | 1 |
| Barbee, LA | 2 |
| Nayak, SU | 1 |
| Blumer, JL | 1 |
| OʼRiordan, MA | 1 |
| Gray, W | 1 |
| Zenilman, JM | 1 |
| Golden, MR | 2 |
| Griffiss, JM | 1 |
| Tanaka, M | 1 |
| Furuya, R | 1 |
| Kobayashi, I | 1 |
| Kanesaka, I | 1 |
| Ohno, A | 1 |
| Katsuse, AK | 1 |
| Singh, A | 1 |
| Tomberg, J | 1 |
| Nicholas, RA | 1 |
| Davies, C | 1 |
| Sriruttan, C | 1 |
| Müller, EE | 1 |
| Gumede, L | 1 |
| Fick, D | 1 |
| de Wet, J | 1 |
| Maseko, V | 1 |
| Coetzee, J | 1 |
| Kerndt, P | 1 |
| Allen, VG | 3 |
| Low, DE | 3 |
| Kirkcaldy, RD | 4 |
| Bolan, GA | 2 |
| Wasserheit, JN | 2 |
| Wright, DJ | 1 |
| Azadian, B | 1 |
| Ison, CA | 10 |
| Town, K | 4 |
| Obi, C | 3 |
| Chisholm, S | 3 |
| Livermore, DM | 2 |
| Lowndes, CM | 4 |
| Nakayama, S | 3 |
| Morita-Ishihara, T | 2 |
| Dorin, M | 1 |
| Kawahata, T | 2 |
| Singh, AE | 3 |
| Read, R | 3 |
| Lovgren, M | 2 |
| Drews, SJ | 2 |
| Romanowski, B | 1 |
| Sutherland, K | 2 |
| Talbot, J | 1 |
| Kidd, S | 2 |
| Lee, MV | 2 |
| Maningas, E | 1 |
| Komeya, A | 1 |
| Kunimoto, G | 1 |
| O'Connor, N | 2 |
| Katz, AR | 1 |
| Wasserman, GM | 1 |
| Whelen, AC | 1 |
| Brooks, B | 1 |
| Cole, M | 1 |
| Ross, JD | 1 |
| White, JA | 1 |
| Patel, R | 1 |
| Bergman, J | 1 |
| Egan, C | 1 |
| McCormick, DF | 1 |
| Rahman, M | 1 |
| Zadrozny, S | 1 |
| Alam, A | 1 |
| Ashraf, L | 1 |
| Neilsen, GA | 1 |
| Kelly, R | 1 |
| Menezes, P | 1 |
| Miller, WC | 1 |
| Kovari, H | 1 |
| de Melo Oliveira, MD | 1 |
| Hauser, P | 1 |
| Läuchli, S | 1 |
| Meyer, J | 1 |
| Weber, R | 1 |
| Zbinden, R | 1 |
| Trees, D | 1 |
| Dordel, J | 1 |
| Harris, SR | 1 |
| Goldstein, E | 1 |
| Parkhill, J | 1 |
| Hanage, WP | 1 |
| Bentley, S | 1 |
| Lipsitch, M | 1 |
| Quaye, N | 1 |
| Yu, RX | 2 |
| Yin, Y | 2 |
| Wang, GQ | 1 |
| Chen, SC | 2 |
| Zheng, BJ | 2 |
| Dai, XQ | 2 |
| Han, Y | 2 |
| Li, Q | 1 |
| Zhang, GY | 2 |
| Chen, X | 1 |
| Dillon, JA | 2 |
| Starnino, S | 1 |
| Endimiani, A | 1 |
| Guilarte, YN | 1 |
| Tinguely, R | 1 |
| Hirzberger, L | 1 |
| Selvini, S | 1 |
| Lupo, A | 1 |
| Hauser, C | 1 |
| Furrer, H | 1 |
| La Ruche, G | 1 |
| Sednaoui, P | 2 |
| Berçot, B | 1 |
| Cambau, E | 1 |
| Semaille, C | 1 |
| Deguchi, T | 6 |
| Tsuchiya, T | 1 |
| Yokoi, S | 4 |
| Donovan, B | 1 |
| Whiley, DM | 2 |
| Furubayashi, K | 1 |
| Chisholm, SA | 3 |
| Hoffmann, S | 2 |
| Van de Laar, M | 2 |
| Cheng, CW | 1 |
| Li, LH | 1 |
| Su, CY | 1 |
| Li, SY | 1 |
| Yen, MY | 1 |
| Grigorjev, V | 1 |
| Peters, RP | 1 |
| Verweij, SP | 1 |
| McIntyre, JA | 1 |
| Schaftenaar, E | 1 |
| Stafforini, G | 1 |
| Carannante, A | 1 |
| Vacca, P | 1 |
| Ghisetti, V | 1 |
| Latino, MA | 1 |
| Cusini, M | 1 |
| Matteelli, A | 1 |
| Vocale, C | 1 |
| Prignano, G | 1 |
| Leli, C | 1 |
| Ober, P | 1 |
| Antonetti, R | 1 |
| Poletti, F | 1 |
| Stefanelli, P | 1 |
| Cresswell, F | 1 |
| Dean, G | 1 |
| Dave, J | 1 |
| Thomas, DR | 1 |
| Foster, K | 1 |
| Waldram, A | 1 |
| Wilson, DJ | 1 |
| Peto, TE | 1 |
| Brunner, A | 1 |
| Nemes-Nikodem, E | 1 |
| Jeney, C | 1 |
| Szabo, D | 1 |
| Marschalko, M | 1 |
| Karpati, S | 1 |
| Ostorhazi, E | 1 |
| Costa-Lourenço, APR | 1 |
| Abrams, JA | 1 |
| Barros Dos Santos, KT | 1 |
| Coelho-Souza, T | 1 |
| Moreira, BM | 1 |
| Fracalanzza, SEL | 1 |
| Trees, DL | 2 |
| Bonelli, RR | 1 |
| Chen, XS | 1 |
| Tapsall, JW | 2 |
| Plitt, S | 1 |
| Boyington, C | 1 |
| Tilley, P | 1 |
| Watanabe, Y | 1 |
| Ono, E | 1 |
| Takahashi, C | 1 |
| Oya, H | 1 |
| Kuroki, T | 1 |
| Okazaki, N | 1 |
| Watanabe, H | 1 |
| Brill, JR | 1 |
| Nakane, K | 1 |
| Maeda, S | 3 |
| Hellmark, B | 1 |
| Fredlund, H | 1 |
| Nissen, MD | 1 |
| Sloots, TP | 1 |
| Klingler, A | 1 |
| Farrell, DJ | 1 |
| Rebbapragada, A | 2 |
| Tan, J | 1 |
| Tijet, N | 1 |
| Perusini, SJ | 1 |
| Towns, L | 2 |
| Lo, S | 1 |
| Syversen, G | 1 |
| Vestrheim, DF | 2 |
| Moi, H | 2 |
| Hussey, J | 1 |
| Sankar, KN | 1 |
| Evans, J | 1 |
| Alexander, S | 3 |
| Hartgill, U | 1 |
| Jakopanec, I | 1 |
| Limnios, A | 1 |
| Tapsall, J | 1 |
| Kahlmeter, J | 1 |
| Hogan, T | 1 |
| Ray, S | 1 |
| Lam, A | 1 |
| Forsyth, S | 1 |
| Penney, P | 1 |
| Rooney, G | 1 |
| Desouza-Thomas, L | 1 |
| Maclure-Webster, E | 1 |
| Anderson, J | 1 |
| Nichols, T | 1 |
| Bala, M | 1 |
| Stary, A | 1 |
| Eigentler, A | 1 |
| Nicholas, R | 1 |
| Gallay, A | 1 |
| Hjelmevoll, SO | 1 |
| Olsen, ME | 1 |
| Sollid, JU | 1 |
| Haaheim, H | 1 |
| Melby, KK | 1 |
| Skogen, V | 1 |
| Sawatzky, P | 1 |
| Allen, V | 1 |
| Hoang, L | 1 |
| Mina, N | 1 |
| Wong, T | 1 |
| Gilmour, M | 1 |
| Bai, ZG | 1 |
| Bao, XJ | 1 |
| Cheng, WD | 1 |
| Yang, KH | 1 |
| Li, YP | 1 |
| Hashimoto, J | 1 |
| Uehara, T | 1 |
| Iwasawa, A | 1 |
| Nishimura, M | 1 |
| Sunaoshi, K | 1 |
| Takeda, K | 1 |
| Suzuki, N | 1 |
| Tsukamoto, T | 1 |
| Kirkcaldy, R | 1 |
| Bolan, G | 1 |
| Pereira, R | 1 |
| Maldonado, NG | 1 |
| Takhar, SS | 1 |
| Mitterni, L | 1 |
| Seah, C | 1 |
| Martin, IE | 1 |
| Lee, C | 1 |
| Siebert, H | 1 |
| Ishida, K | 1 |
| Ishihara, S | 2 |
| Minamidate, K | 1 |
| Harada, Y | 1 |
| Tei, K | 1 |
| Kojima, K | 1 |
| Tamaki, M | 2 |
| Wang, SA | 1 |
| Iverson, CJ | 1 |
| Ohye, RG | 1 |
| Whiticar, PM | 1 |
| Hale, JA | 1 |
| Knapp, JS | 1 |
| Effler, PV | 1 |
| Weinstock, HS | 1 |
| Levenson, D | 1 |
| Mizutani, KS | 1 |
| Takahashi, Y | 1 |
| Kawamura, Y | 1 |
| Ezaki, T | 1 |
| Whittington, WL | 2 |
| Handsfield, HH | 2 |
| Hughes, JP | 1 |
| Stamm, WE | 1 |
| Hogben, M | 1 |
| Clark, A | 1 |
| Malinski, C | 1 |
| Helmers, JR | 1 |
| Thomas, KK | 1 |
| Holmes, KK | 2 |
| Barlam, TF | 1 |
| Little, JW | 1 |
| Asbel, LE | 1 |
| Newbern, EC | 1 |
| Salmon, M | 1 |
| Spain, CV | 1 |
| Goldberg, M | 1 |
| Takahata, S | 1 |
| Senju, N | 1 |
| Osaki, Y | 1 |
| Yoshida, T | 1 |
| Ida, T | 1 |
| McMillan, A | 1 |
| Young, H | 1 |
| Sathia, L | 1 |
| Ellis, B | 1 |
| Phillip, S | 1 |
| Winston, A | 1 |
| Smith, A | 1 |
| Ozawa, T | 1 |
| Kubota, Y | 1 |
| Dalla Vestra, M | 1 |
| Rettore, C | 1 |
| Sartore, P | 1 |
| Velo, E | 1 |
| Sasset, L | 1 |
| Chiesa, G | 1 |
| Marcon, L | 1 |
| Scarano, L | 1 |
| Simioni, N | 1 |
| Bacelle, L | 1 |
| Patrassi, GM | 1 |
| Klepser, ME | 1 |
| Quintiliani, R | 1 |
| Nightingale, CH | 1 |
| Loughlin, KA | 1 |
| Bakst, CM | 1 |
| Rybak, MJ | 1 |
| Friedland, LR | 1 |
| Kulick, RM | 1 |
| Biro, FM | 1 |
| Patterson, A | 1 |
| Tu, Y | 1 |
| Kratofiel, M | 1 |
| Petzoldt, D | 1 |
| Hook, EW | 2 |
| McCormack, WM | 2 |
| Martin, D | 1 |
| Jones, RB | 1 |
| Bean, K | 1 |
| Maroli, AN | 1 |
| Crabbé, F | 1 |
| Vuylsteke, B | 1 |
| de Clerck, M | 1 |
| Laga, M | 1 |
| Aplasca De Los Reyes, MR | 1 |
| Pato-Mesola, V | 1 |
| Manalastas, R | 1 |
| Tuazon, CU | 1 |
| Dallabetta, G | 1 |
| Ramus, RM | 1 |
| Sheffield, JS | 1 |
| Mayfield, JA | 1 |
| Wendel, GD | 1 |
| Plourde, PJ | 1 |
| Tyndall, M | 1 |
| Agoki, E | 1 |
| Ombette, J | 1 |
| Slaney, LA | 1 |
| D'Costa, LJ | 1 |
| Ndinya-Achola, JO | 1 |
| Plummer, FA | 1 |
| Holdcroft, C | 1 |
| Asbach, HW | 1 |
| Di Nola, F | 1 |
| Arione, R | 1 |
| Bramato, C | 1 |
| Douglas, JM | 1 |
| Covino, JM | 1 |
| Verdon, MS | 1 |
| Reichart, CA | 1 |
| Ehret, JM | 1 |
| Cates, W | 1 |
| Hinman, AR | 1 |
| Backhaus, A | 1 |
| Tinzl, J | 1 |
| Megran, DW | 1 |
| Lefebvre, K | 1 |
| Willetts, V | 1 |
| Bowie, WR | 1 |
| Kuhlwein, A | 1 |
| Nies, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Efficacy of Two Combination Regimens for the Treatment of Uncomplicated Neisseria Gonorrhoeae and Chlamydia Trachomatis Coinfection[NCT05216744] | Phase 2 | 125 participants (Actual) | Interventional | 2021-07-15 | Completed | ||
| The Pharmacokinetics of Extended Duration High-Dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study[NCT01949363] | Phase 1 | 25 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis in Non-pregnant Women[NCT03752112] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2019-11-22 | Recruiting | ||
| Performance of Nucleic Acid Amplification Tests for the Detection of Neisseria Gonorrhoeae and Chlamydia Trachomatis in Extragenital Sites[NCT02870101] | 2,767 participants (Actual) | Interventional | 2017-04-10 | Completed | |||
| Repeat STI Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk[NCT01510262] | 130 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for cefixime and Gonorrhea
| Article | Year |
|---|---|
Effectiveness of Cefixime for the Treatment of Neisseria gonorrhoeae Infection at 3 Anatomic Sites: A Systematic Review and Meta-Analysis.
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Gonorrhea; Humans; Microbial Sensitivity Tests; Neisse | 2023 |
Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multiple | 2020 |
Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis.
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Gentamicins; Gonorrhea; Humans; Injections, Intramuscu | 2021 |
Antibiotics for treating gonorrhoea in pregnancy.
Topics: Amoxicillin; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Female; Gonorrhea; Humans; Pregnancy; Pre | 2018 |
Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Cefixime; Cefpodoxime; Ceftizoxime; Female; Gonorrhea; Humans; Male; Neisseri | 2014 |
Preparing for an era of untreatable gonorrhea.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporin Resistance; Cephalosporins | 2014 |
Emergence and spread of drug resistant Neisseria gonorrhoeae.
Topics: Azithromycin; Cefixime; Drug Resistance, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Neisseria g | 2010 |
Antimicrobial resistance in Neisseria gonorrhoeae in the UK: surveillance and management.
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Disease Management; Drug Resistance, Multiple, Bacteri | 2011 |
Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Gonorrhea; Humans; Middle Aged; Odd | 2012 |
[Gonorrhea].
Topics: Anti-Bacterial Agents; Cefixime; Gonorrhea; Humans; Practice Guidelines as Topic; Practice Patterns, | 2006 |
Treatment of uncomplicated infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Cefotaxime; Chlamydia Infections; Chlamydia trachomat | 1994 |
Oral treatment of gonorrhea and chlamydia.
Topics: Administration, Oral; Anti-Infective Agents; Cefixime; Cefotaxime; Chlamydia Infections; Ciprofloxac | 1994 |
Gonorrhoea: single-dose oral treatment.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Cefotaxi | 1996 |
[Cefixime. Microbiologic, kinetic and clinical profile].
Topics: Animals; Bacteria; Cefixime; Cefotaxime; Gonorrhea; Humans; Microbial Sensitivity Tests; Otitis Medi | 1991 |
13 trials available for cefixime and Gonorrhea
| Article | Year |
|---|---|
Randomized controlled trial of the relative efficacy of high-dose intravenous ceftriaxone and oral cefixime combined with doxycycline for the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae co-infection.
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Chlamydia Infections; Chlamydia trachomatis; Coinfecti | 2022 |
Optimisation of treatments for oral
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Gonorrhea; Humans; Male; Neisseria gonorrhoeae | 2022 |
A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cephalosporins; Cohort Stu | 2018 |
A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cephalosporins; Cohort Stu | 2018 |
A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cephalosporins; Cohort Stu | 2018 |
A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cephalosporins; Cohort Stu | 2018 |
Prevention and control of sexually transmissible infections among hotel-based female sex workers in Dhaka, Bangladesh.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Bangladesh; Candidiasis, Vulvovaginal; Cefixime; Ch | 2013 |
Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Chlamydia Infections; Contact Tracing; Drug Th | 2005 |
Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group.
Topics: Administration, Oral; Adolescent; Anti-Infective Agents; beta-Lactam Resistance; Cefixime; Cefotaxim | 1997 |
A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines.
Topics: Adolescent; Adult; Anti-Infective Agents; Cefixime; Cephalosporins; Ciprofloxacin; Drug Resistance, | 2001 |
A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy.
Topics: Administration, Oral; Adolescent; Adult; Anus Diseases; Cefixime; Ceftriaxone; Cephalosporins; Chlam | 2001 |
Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Cefixime; Cefotaxime; Ceftriaxone; Drug Ev | 1992 |
Cefixime offers effective oral therapy for gonorrhea.
Topics: Anti-Infective Agents, Urinary; Cefixime; Cefotaxime; Ceftriaxone; Female; Gonorrhea; Humans; Male | 1992 |
Single dose oral administration of cefixime 400mg in the treatment of acute uncomplicated cystitis and gonorrhoea.
Topics: Acute Disease; Administration, Oral; Cefixime; Cefotaxime; Cystitis; Double-Blind Method; Female; Go | 1991 |
A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cefixime; Cefotaxime; Ceftriaxone; Drug Resistance, Microbi | 1991 |
Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men.
Topics: Adolescent; Adult; Amoxicillin; Cefixime; Cefotaxime; Gonorrhea; Humans; Male; Probenecid; Randomize | 1990 |
132 other studies available for cefixime and Gonorrhea
| Article | Year |
|---|---|
Multidrug-resistant Neisseria gonorrhoeae infection in heterosexual men with reduced susceptibility to ceftriaxone, first report in Thailand.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Drug | 2021 |
Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Female; Gentamicins; Gono | 2022 |
Is there an association between previous infection with
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cross-Sectional Studies; Drug Resistance, Bacterial; E | 2023 |
Markedly Increasing Antibiotic Resistance and Dual Treatment of Neisseria gonorrhoeae Isolates in Guangdong, China, from 2013 to 2020.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporin Resistance; Cephalosporins | 2022 |
WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria | 2021 |
Europe-wide expansion and eradication of multidrug-resistant Neisseria gonorrhoeae lineages: a genomic surveillance study.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Europe; Geno | 2022 |
Significant increase in azithromycin "resistance" and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Dr | 2022 |
Resistance-Guided Therapy for Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Gonorrhea; | 2022 |
Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates From Peru, 2018 and 2019.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria | 2022 |
Whole-genome sequence analysis of high-level penicillin-resistant strains and antimicrobial susceptibility of Neisseria gonorrhoeae clinical isolates from Thailand.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Go | 2022 |
Topics: Cefixime; Cephalosporin Resistance; Gonorrhea; Humans; Microbial Sensitivity Tests; Neisseria gonorr | 2022 |
Loop-Mediated Isothermal Amplification Assay for Identifying Neisseria gonorrhoeae Nonmosaic
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gon | 2022 |
Right hip gonococcal septic arthritis treatment with successful transition to oral fluoroquinolone.
Topics: Anti-Bacterial Agents; Arthritis, Infectious; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, | 2022 |
Characterizing the Rise of Disseminated Gonococcal Infections in California, July 2020-July 2021.
Topics: Adult; Anti-Bacterial Agents; California; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorrh | 2023 |
Multicentre Clinical Evaluation of a Molecular Diagnostic Assay to Identify Neisseria gonorrhoeae Infection and Detect Antimicrobial Resistance.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorrhea; H | 2023 |
Emergence of a predominant sequence type ST7363 and the increasing trend of resistance to cefixime and ceftriaxone in Neisseria gonorrhoeae in Southern Taiwan, 2019-2021.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonor | 2023 |
Projecting the development of antimicrobial resistance in Neisseria gonorrhoeae from antimicrobial surveillance data: a mathematical modelling study.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria | 2023 |
Dissemination of Neisseria gonorrhoeae with decreased susceptibility to extended-spectrum cephalosporins in Southern China, 2021: a genome-wide surveillance from 20 cities.
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cephalosporins; Cities; Gonorrhea; Humans; Microbial S | 2023 |
Antimicrobial Resistance Profiling and Genome Analysis of the penA-60.001 Neisseria gonorrhoeae Clinical Isolates in China in 2021.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorrhea; H | 2023 |
Correlates of
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Cross-Sectional St | 2023 |
The third nationwide surveillance of antimicrobial susceptibility against Neisseria gonorrhoeae from male urethritis in Japan, 2016-2017.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone; Gonorrhea; Humans | 2023 |
Use of genome sequencing to resolve differences in gradient diffusion and agar dilution antimicrobial susceptibility testing performance of
Topics: Agar; Alberta; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Gonorrhea; | 2023 |
Six penA Codons Accurately and Reliably Predict Cefixime-Decreased Susceptibility in Neisseria gonorrhoeae.
Topics: Azithromycin; Cefixime; Ceftriaxone; Cephalosporins; Codon; Evolution, Molecular; Gonorrhea; Humans; | 2020 |
The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ciprofloxacin; Drug Resistance, Bacterial; European U | 2019 |
Antimicrobial resistance of Neisseria gonorrhoeae in Jakarta, Indonesia: a cross-sectional study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cross-Sectional Studie | 2020 |
First Case of High-Level Azithromycin-Resistant Neisseria gonorrhoeae in North Carolina.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonor | 2020 |
Antimicrobial Resistance of Neisseria Gonorrhoeae in a Newly Implemented Surveillance Program in Uganda: Surveillance Report.
Topics: Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Ciprofloxacin; Demography; Drug Resistance, Bac | 2020 |
Cephalosporin-Resistant Neisseria gonorrhoeae Isolated in Portugal, 2019.
Topics: Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Gonorrhea | 2020 |
External quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in primary laboratories in Germany.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria | 2020 |
Molecular epidemiological typing of
Topics: Adult; Cefixime; Drug Resistance, Multiple, Bacterial; Female; Germany; Gonorrhea; Humans; Male; Mic | 2020 |
Pain in the eye: a case of gonococcal orbital cellulitis.
Topics: Adult; Cefixime; Ciprofloxacin; Female; Gonorrhea; Humans; Neisseria gonorrhoeae; Orbital Cellulitis | 2021 |
Notes from the Field: First Case in the United States of Neisseria gonorrhoeae Harboring Emerging Mosaic penA60 Allele, Conferring Reduced Susceptibility to Cefixime and Ceftriaxone.
Topics: Alleles; Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Gonorrhea; Humans; Male; Neiss | 2020 |
Associations between antimicrobial susceptibility/resistance of Neisseria gonorrhoeae isolates in European Union/European Economic Area and patients' gender, sexual orientation and anatomical site of infection, 2009-2016.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria | 2021 |
In brief: New recommendations for gonococcal infection.
Topics: Anti-Bacterial Agents; Cefixime; Gonorrhea; Humans; Microbial Sensitivity Tests; Sexual Partners | 2021 |
Tracking Antimicrobial Resistance in Neisseria gonorrhoeae from the Molecular Level Using Endocervical Swabs.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Female; Gono | 2022 |
WGS to predict antibiotic MICs for Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Canada; Cefixime; Ciprofloxacin; Drug Resistance, Bacterial; En | 2017 |
A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Dr | 2017 |
Antimicrobial susceptibility in
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Disk D | 2018 |
Emergence and Spread of Neisseria gonorrhoeae Isolates With Decreased Susceptibility to Extended-Spectrum Cephalosporins in Argentina, 2009 to 2013.
Topics: Anti-Bacterial Agents; Argentina; Cefixime; Ceftriaxone; Cephalosporin Resistance; Gonorrhea; Humans | 2017 |
Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporin R | 2017 |
High levels of susceptibility to new and older antibiotics in Neisseria gonorrhoeae isolates from Saskatchewan (2003-15): time to consider point-of-care or molecular testing for precision treatment?
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Child; Child, P | 2018 |
Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: A modelling study.
Topics: Anti-Bacterial Agents; Asymptomatic Infections; Bisexuality; Cefixime; Cephalosporin Resistance; Cos | 2017 |
Fitness cost and benefit of antimicrobial resistance in Neisseria gonorrhoeae: Multidisciplinary approaches are needed.
Topics: Anti-Bacterial Agents; Cefixime; Drug Resistance, Bacterial; Gonorrhea; Humans; Microbial Sensitivit | 2017 |
Accuracy and reproducibility of the Etest to detect drug-resistant Neisseria gonorrhoeae to contemporary treatment.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorrhea; H | 2018 |
Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporin Resistance; Cervix | 2018 |
Antimicrobial resistance and molecular characterisation of Neisseria gonorrhoeae isolates in Fukuoka, Japan, 1996-2016.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorr | 2019 |
Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxo | 2018 |
Using the genetic characteristics of Neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility.
Topics: Anti-Bacterial Agents; Cefixime; Drug Resistance, Bacterial; Gonorrhea; Humans; Microbial Sensitivit | 2019 |
Recognition of the β-lactam carboxylate triggers acylation of
Topics: Acylation; Alleles; Binding Sites; Catalytic Domain; Cefixime; Ceftriaxone; Cephalosporin Resistance | 2019 |
Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure.
Topics: Adult; Anti-Bacterial Agents; Bacterial Typing Techniques; Cefixime; Cefpodoxime; Ceftizoxime; Cepha | 2013 |
Cephalosporin resistance in Neisseria gonorrhoeae infections.
Topics: Anti-Bacterial Agents; Cefixime; Female; Gonorrhea; Humans; Male; Neisseria gonorrhoeae | 2013 |
Cephalosporin resistance in Neisseria gonorrhoeae infections--reply.
Topics: Anti-Bacterial Agents; Cefixime; Female; Gonorrhea; Humans; Male; Neisseria gonorrhoeae | 2013 |
Cephalosporin resistance in Neisseria gonorrhoeae infections--reply.
Topics: Anti-Bacterial Agents; Cefixime; Female; Gonorrhea; Humans; Male; Neisseria gonorrhoeae | 2013 |
Cephalosporin resistance in gonorrhoea.
Topics: Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Humans; Male; Neisse | 2013 |
Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacteria | 2013 |
Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftriaxone resistance.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; beta-Lactam Resistance; Cefixime; Ceftriax | 2013 |
Neisseria gonorrhoeae multiantigen sequence typing is beneficial in further characterizing gonococcal populations in Alberta, Canada.
Topics: Alberta; Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; Bacterial Typing Techniques; Cefi | 2013 |
Gonococcal susceptibility to cephalosporins--Hawaii, 2003 to 2011.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cefpodoxime; Ceftizoxime; Ceftriaxone; Drug Resi | 2013 |
Does the '2012 IUSTI ECCG report on the diagnosis and management of Neisseria gonorrhoeae infections in Europe' depict the situation in Europe?
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Disease Management; Europe; Gonorrhea; Health Services | 2013 |
Retrospective review of pharyngeal gonorrhea treatment failures in Alberta, Canada.
Topics: Adult; Alberta; Anti-Bacterial Agents; Azithromycin; Cefixime; Drug Therapy, Combination; Female; Go | 2013 |
Decreased susceptibility of Neisseria gonorrhoeae isolates from Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxo | 2013 |
Phylogenomics for drug-resistant Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Cefixime; Cephalosporin Resistance; Gonorrhea; Humans; Male; Neisseria gonorr | 2014 |
Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study.
Topics: Anti-Bacterial Agents; Cefixime; Cephalosporin Resistance; Genome, Bacterial; Genotype; Gonorrhea; H | 2014 |
Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefixime; Ertapenem; Gonorrhea; Humans; Inhibitory Concentratio | 2014 |
Molecular epidemiology of Neisseria gonorrhoeae isolates from Saskatchewan, Canada: utility of NG-MAST in predicting antimicrobial susceptibility regionally.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Bacterial Typing Techniques; Cefixime; | 2014 |
Unique combined penA/mtrR/porB mutations and NG-MAST strain types associated with ceftriaxone and cefixime MIC increases in a 'susceptible' Neisseria gonorrhoeae population.
Topics: Amino Acid Substitution; Bacterial Proteins; Canada; Cefixime; Ceftriaxone; Drug Resistance, Bacteri | 2014 |
Characterization of Neisseria gonorrhoeae isolates detected in Switzerland (1998-2012): emergence of multidrug-resistant clones less susceptible to cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporins; Child | 2014 |
Decreased susceptibility to cephalosporins among gonococci?
Topics: Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Humans; Male; Neisse | 2014 |
Decreased susceptibility to cephalosporins among gonococci?
Topics: Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Humans; Male; Neisse | 2014 |
Decreased susceptibility to cephalosporins among gonococci? Authors' reply.
Topics: Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Humans; Male; Neisse | 2014 |
Decreased susceptibility to cephalosporins among gonococci?
Topics: Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Humans; Male; Neisse | 2014 |
Mitigating the emergence and spread of multidrug- and extensively drug-resistant gonorrhea: is there sufficient support in resource-poor settings in Africa?
Topics: Africa; Anti-Bacterial Agents; Cefixime; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Gu | 2014 |
Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Bacterial Typing Techniques; Ce | 2014 |
Emerging cephalosporin and multidrug-resistant gonorrhoea in Europe.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Europe; E | 2014 |
Changes in the six most common sequence types of Neisseria gonorrhoeae, including ST4378, identified by surveillance of antimicrobial resistance in northern Taiwan from 2006 to 2013.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Cefixime; Cefpodoxime; Ceftizoxime; Ceftriaxone; Ciprofl | 2016 |
Can previous first-line therapies for Neisseria gonorrhoeae be targeted to specific patient subgroups to treat gonorrhea?
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Ciprofloxacin; Drug Resistance, Bacterial; Engla | 2015 |
Risk factors for antimicrobial-resistant Neisseria gonorrhoeae in Europe.
Topics: Adult; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Microbial; Europ | 2014 |
Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance.
Topics: Adult; Anti-Bacterial Agents; Cefixime; Cephalosporin Resistance; Europe; Female; Gonorrhea; Humans; | 2015 |
Gonococcal Conjunctivitis Despite Successful Treatment of Male Urethritis Syndrome.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Conjunctivitis; Gonorrhea; Humans; Male; Neisseria go | 2016 |
Neisseria gonorrhoeae Resistant to Ceftriaxone and Cefixime, Argentina.
Topics: Alleles; Anti-Bacterial Agents; Argentina; beta-Lactam Resistance; beta-Lactamases; Cefixime; Ceftri | 2016 |
Genetic Resistance Determinants for Cefixime and Molecular Analysis of Gonococci Isolated in Italy.
Topics: Alleles; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Cefixime; Ceftriaxone; | 2017 |
Whole-genome sequencing to determine transmission of Neisseria gonorrhoeae: an observational study.
Topics: Adult; Alleles; Anti-Bacterial Agents; Cefixime; Cephalosporin Resistance; Cephalosporins; Female; G | 2016 |
Emerging azithromycin-resistance among the Neisseria gonorrhoeae strains isolated in Hungary.
Topics: Adult; Alleles; Anti-Bacterial Agents; Azithromycin; Bacterial Typing Techniques; Cefixime; Ceftriax | 2016 |
Reduced susceptibility to cefixime but not ceftriaxone: an uncertain perspective for the treatment of gonorrhoea in Brazil.
Topics: Adult; Anti-Bacterial Agents; Brazil; Cefixime; Ceftriaxone; Female; Gonorrhea; High-Throughput Nucl | 2017 |
Antimicrobial Susceptibility Evaluation and Multiple-Locus Variable Number Tandem Repeat Analysis of Neisseria gonorrhoeae Isolates in China in 2012.
Topics: Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cervix Uteri; Chi-Square Distribution; China; C | 2017 |
Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci.
Topics: Anti-Bacterial Agents; Asia, Southeastern; Australia; Cefixime; Cefotaxime; Ceftriaxone; Cephalospor | 2009 |
Antimicrobial resistance in gonorrhea: the influence of epidemiologic and laboratory surveillance data on treatment guidelines: Alberta, Canada 2001-2007.
Topics: Adult; Cefixime; Ciprofloxacin; Drug Resistance, Bacterial; Female; Gonorrhea; Humans; Male; Neisser | 2009 |
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
Topics: Anti-Bacterial Agents; Base Sequence; Cefixime; Cephalosporin Resistance; Chromosomes, Bacterial; Go | 2010 |
Diagnosis and treatment of urethritis in men.
Topics: Adolescent; Adult; Azithromycin; Black or African American; Cefixime; Ceftriaxone; Chlamydia Infecti | 2010 |
Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antigens, Bacterial; Cefixime; Ceftriaxone; Communic | 2010 |
Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cephalosporin Resistance; Fimbria | 2010 |
Quick recertification series. Gonorrhea.
Topics: Administration, Oral; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Female; Gonorrhea; Humans; Injec | 2010 |
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Cefixime; Ceftriaxone; Cephalosporin | 2011 |
Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010.
Topics: Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorrhea; Humans; | 2010 |
Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Drug Resistance, Multiple, Bacterial; England; Female | 2011 |
[Gonorrhea--time for new guidelines].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefixime; Ciprofloxacin; Drug Resistance, Bacterial; F | 2011 |
Cefpodoxime 10 μg disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes.
Topics: Alleles; Anti-Bacterial Agents; Cefixime; Cefpodoxime; Ceftizoxime; Ceftriaxone; Cephalosporins; Dos | 2011 |
Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations.
Topics: Adult; Anti-Bacterial Agents; Cefixime; Drug Resistance, Bacterial; Gonorrhea; Humans; Male; Microbi | 2011 |
Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010.
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cephalosporins; Drug Resistance, Bacterial; Female; Go | 2011 |
Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cefixime; Ciprofloxacin; Drug Resistance, Multiple, | 2011 |
Characterization of profile of multidrug-resistant Neisseria gonorrhoeae using old and new definitions in India over a decade: 2000-2009.
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Gonorrhea; Human | 2011 |
First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011.
Topics: Anti-Bacterial Agents; Austria; Cefixime; Cephalosporin Resistance; Gonorrhea; Humans; Male; Neisser | 2011 |
High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.
Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Biomarkers; Cefixime; Ceftriaxone; Cephalospori | 2012 |
Appropriate time for test-of-cure when diagnosing gonorrhoea with a nucleic acid amplification test.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cefixime; Cervix Uteri; Ciprofloxacin; Drug Resistan | 2012 |
Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010.
Topics: Adolescent; Adult; Canada; Cefixime; Ceftriaxone; Drug Resistance, Microbial; Female; Gonorrhea; Hum | 2012 |
Management of pharyngeal gonorrhea is crucial to prevent the emergence and spread of antibiotic-resistant Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cephalosporin Resistance; Gonorrhea; Humans; Male; Nei | 2012 |
Antimicrobial susceptibility and penicillin-binding protein 1 and 2 mutations in Neisseria gonorrhoeae isolated from male urethritis in Sapporo, Japan.
Topics: Anti-Bacterial Agents; Cefixime; Cephalosporin Resistance; Cephalosporins; Gonorrhea; Humans; Japan; | 2013 |
Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections.
Topics: Administration, Oral; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Centers for Diseas | 2012 |
Tackling multidrug-resistant gonorrhea: how should we prepare for the untreatable?
Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Gonorrhea; Human | 2012 |
Combination therapy for gonorrhoea: in vitro synergy testing.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Synergism; Gentamicins; Gonorrhea; | 2013 |
Update on Emerging Infections: news from the Centers for Disease Control and Prevention. Update to the CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections .
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Doxycycline; Female; Gonorrhea; Humans; | 2013 |
Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada.
Topics: Adult; Anti-Bacterial Agents; Cefixime; Cohort Studies; Drug Resistance, Microbial; Female; Gonorrhe | 2013 |
Cephalosporin-resistant gonorrhea in North America.
Topics: Anti-Bacterial Agents; Cefixime; Female; Gonorrhea; Humans; Male; Neisseria gonorrhoeae | 2013 |
Discontinuation of cefixime tablets--United States.
Topics: Anti-Bacterial Agents; Cefixime; Drug and Narcotic Control; Drug Resistance, Bacterial; Gonorrhea; N | 2002 |
Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval.
Topics: Anti-Bacterial Agents; Cefixime; Drug Administration Schedule; Gonorrhea; Humans; Male; Microbial Se | 2003 |
Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime-Hawaii, 2001.
Topics: Adult; Anti-Infective Agents; Cefixime; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gonorr | 2003 |
Increasing cases of drug-resistant gonorrhea prompt new CDC treatment recommendations for gay and bisexual men.
Topics: Cefixime; Ceftizoxime; Ceftriaxone; Centers for Disease Control and Prevention, U.S.; Contraindicati | 2004 |
Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Cefixime; Drug Resistance, Bact | 2005 |
Expedited treatment for partners of patients with gonorrhea and/or chlamydial infection: impact on rates of persistence or recurrence.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Chlamydia Infections; Drug Therapy, Combinatio | 2005 |
Gonorrhea: update.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Child; Gonorrhea; Humans; Incidence | 2006 |
School-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae among Philadelphia public high school students.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Child; Chlam | 2006 |
Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae.
Topics: Amino Acid Sequence; Amino Acid Substitution; Bacterial Proteins; Cefixime; Cephalosporins; Cloning, | 2006 |
The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime.
Topics: Administration, Oral; Anti-Bacterial Agents; Cefixime; Chlamydia Infections; Chlamydia trachomatis; | 2007 |
Pharyngeal gonorrhoea - is dual therapy the way forward?
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Chlamydia Infections; Doxycycline; Drug Therapy, Comb | 2007 |
Threat to cefixime treatment for gonorrhea.
Topics: Adult; Base Sequence; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulse | 2007 |
Availability of cefixime 400 mg tablets--United States, April 2008.
Topics: Anti-Bacterial Agents; Cefixime; Gonorrhea; Humans; United States | 2008 |
Acute septic arthritis: remember gonorrhea.
Topics: Acute Disease; Anti-Bacterial Agents; Arthritis, Infectious; Cefixime; Ceftriaxone; Gonorrhea; Human | 2008 |
Cost-effectiveness decision analysis of intramuscular ceftriaxone versus oral cefixime in adolescents with gonococcal cervicitis.
Topics: Administration, Oral; Adolescent; Anti-Infective Agents; Cefixime; Cefotaxime; Ceftriaxone; Cephalos | 1996 |
Cost-effectiveness of management strategies for acute urethritis in the developing world.
Topics: Acute Disease; Anti-Bacterial Agents; Anti-Infective Agents; Cefixime; Cost-Benefit Analysis; Decisi | 2000 |
Sexually transmitted diseases in the 1990s.
Topics: Cefixime; Cefotaxime; Ceftriaxone; Gonorrhea; HIV Infections; Humans; Sexually Transmitted Diseases | 1991 |
[Cefixime therapy in patients with proven gonorrhea].
Topics: Acute Disease; Adult; Anti-Infective Agents; Cefixime; Cefotaxime; Drug Tolerance; Gonorrhea; Humans | 1990 |
Efficacy and safety of a single 400 mg oral dose of cefixime in the treatment of uncomplicated gonorrhea.
Topics: Administration, Oral; Adolescent; Adult; Cefixime; Cefotaxime; Gonorrhea; Humans; Male; Neisseria go | 1989 |